Inborn Errors of Metabolism Disorders

2

Review clinical trials related to Inborn Errors of Metabolism Disorders. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Available

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

The objective of this study is to make T-cell depleted stem cells from a family member who is a half match (haplo-identical) available on an expanded access basis to patients receiving one or two unrelated cord blood transplants who are at a higher risk of not engrafting in a safe amount of time. The purpose of the related stem cells is to give the bone marrow a "jump start" towards recovery. Ultimately, the cord blood cells will grow and permanently rescue the bone marrow.

Trial details
Age: Up to 65Biological sex: AllType: Expanded AccessSponsor: Joanne Kurtzberg, MDUpdated: Nov 20, 2025Locations: 1
Eligibility criteria

Have a consenting related haplo-identical (3/6, 4/6, or 5/6 if DRB1 mismatch) st... [+5]

Have a consenting 8/8 or 10/10 allele matched, consenting, related or unrelated... [+2]

Status: Recruiting

Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare Disease Patients

"Rare Diseases" is an umbrella term including more than 8.000 different diseases which individually affect only a small percentage of people. Rare diseases predominantly affect children and adolescents and are associated with high medical and psychosocial burden of disease. The investigators invented Education \& Care in RARE - a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. This study is a prospective, multicenter, randomized and controlled study with a waiting list. Aim of the study is to investigate the efficacy of Education \& Care in RARE on knowledge about rare diseases and on mental health well-being in pediatric rare disease patients, compared to a control group. In this study participants are randomized in an intervention group and a waiting list control group. Both study groups thus receive the psychoeducation with Education \& Care in RARE and complete the identical questionnaires. Compared to the Intervention group, the waiting list control group receives the intervention with a time delay (8-12 weeks later) and has one additional appointment for questionnaire evaluation before start of the psychoeducation.

Participants needed: 100
Trial details
Age: 5-20Biological sex: AllType: InterventionalSponsor: Medical University of ViennaUpdated: May 13, 2025Locations: 7
Eligibility criteria

Children and adolescents with a confirmed diagnosis of a rare disease with [+5]

Moderate or severe cognitive impairment [+4]